111, Inc.
YI · NASDAQ Global Market · USD
2,929USD
+0,015 (+0,51 %)Stand 9. Nov., 21:00
Nachbörslich2,94+0,011 (+0,38 %)19:00 ET
Kennzahlen
- Eröffnung
- 2,92
- Vortag
- 2,914
- Tagesspanne
- 2,92 – 2,97
- 52 Wochen
- 2,48 – 11,17
- Volumen
- 721
- Ø Volumen
- 13.356
- Börsenwert
- 25,77 Mio. $
- KGV
- -1,6
- Gewinn je Aktie (TTM)
- -11,92
- Dividendenrendite
- 0,0 %
- Beta
- 0,7
- Nächste Zahlen
- 26. Nov. 2026
Finanzen
| CNY | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Umsatz | 12,21 Mrd. | 14,4 Mrd. | 14,95 Mrd. | 13,52 Mrd. | 12,43 Mrd. |
| Herstellungskosten | 11,51 Mrd. | 13,57 Mrd. | 14,1 Mrd. | 12,68 Mrd. | 11,8 Mrd. |
| Bruttogewinn | 703,7 Mio. | 829,23 Mio. | 848,98 Mio. | 839,98 Mio. | 621,1 Mio. |
| Forschung und Entwicklung | 0 | 0 | 0 | 0 | 0 |
| Vertrieb und Verwaltung | 654,98 Mio. | 384,8 Mio. | 672,59 Mio. | 663,5 Mio. | 720,13 Mio. |
| Operatives Ergebnis | −10,03 Mio. | 2,11 Mio. | −350,1 Mio. | −371 Mio. | −642,14 Mio. |
| EBITDA | 1,81 Mio. | 24,62 Mio. | −311,26 Mio. | −321,81 Mio. | −588,32 Mio. |
| Nettogewinn | −16,84 Mio. | −64,74 Mio. | −392,69 Mio. | −416,88 Mio. | −669,81 Mio. |
| Gewinn je Aktie (verwässert) | -7,42 | -7,52 | -46,58 | -50,04 | -80,76 |
Umsatz nach Segment
Produkte · FY 2025
- Product12,47 Mrd. CNY49,66 %−12,76 %
- Drugs11,65 Mrd. CNY46,39 %−13,05 %
- Nutritional Supplements434,69 Mio. CNY1,73 %−21,03 %
- Other Products233,69 Mio. CNY0,93 %+15,78 %
- Medical Supplies And Devices152,35 Mio. CNY0,61 %+5,59 %
- Service85,38 Mio. CNY0,34 %−19,84 %
- MP Service56,75 Mio. CNY0,23 %−13,41 %
- Service, Other28,63 Mio. CNY0,11 %−30,13 %
Anteil · ggü. Vorjahr (FY 2024)
Bewertung
Letzte 12 Monate
- KGV
- -1,6
- Kurs-Umsatz-Verhältnis
- 0,0
- Kurs-Buchwert-Verhältnis
- -1,5
- PEG
- 0,0
- Bruttomarge
- 5,7 %
- Operative Marge
- −0,5 %
- Nettomarge
- −0,9 %
- Verschuldungsgrad
- -2,5
- EV/EBITDA
- -4,6
- Eigenkapitalrendite
- 23,6 %
- Kapitalrendite (ROIC)
- −11,3 %
- Free-Cashflow-Rendite
- −23,1 %
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Bruttomarge | 5,8 % | 5,8 % | 5,7 % | 6,2 % | 5,0 % |
| Operative Marge | −0,1 % | 0,0 % | −2,3 % | −2,7 % | −5,2 % |
| Nettomarge | −0,1 % | −0,4 % | −2,6 % | −3,1 % | −5,4 % |
| KGV | -2,4 | -6,0 | -2,4 | -4,2 | -2,8 |
| Kurs-Umsatz-Verhältnis | 0,0 | 0,0 | 0,1 | 0,1 | 0,1 |
| Kurs-Buchwert-Verhältnis | -0,2 | -0,6 | -1,6 | -4,2 | -10,6 |
| Verschuldungsgrad | -0,3 | -0,4 | -0,8 | -0,8 | -2,8 |
| Liquidität 3. Grades | 1,1 | 1,1 | 1,1 | 1,2 | 1,3 |
| Dividendenrendite | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
| Unternehmenswert | −188,16 Mio. | 186,33 Mio. | 767,12 Mio. | 1,41 Mrd. | 1,67 Mrd. |
| EV/EBITDA | -103,9 | 7,6 | -2,5 | -4,4 | -2,8 |
| Eigenkapitalrendite | 2,4 % | 10,1 % | 67,3 % | 100,5 % | 386,5 % |
| Kapitalrendite (ROIC) | −2,3 % | 0,3 % | −48,3 % | −37,4 % | −47,9 % |
| Free-Cashflow-Rendite | 73,6 % | 63,2 % | −49,3 % | −3,2 % | −40,8 % |
Wachstum
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Umsatz | −15,2 % | −3,7 % | +10,6 % | +8,8 % | +51,5 % |
| Bruttogewinn | −15,1 % | −2,3 % | +1,1 % | +35,2 % | +69,8 % |
| Operatives Ergebnis | −574,4 % | +100,6 % | +5,6 % | +42,2 % | −35,7 % |
| Nettogewinn | +74,0 % | +83,5 % | +5,8 % | +37,8 % | −46,7 % |
| Gewinn je Aktie | +1,3 % | +83,9 % | +6,9 % | +38,0 % | −45,8 % |
| Freier Cashflow | −53,7 % | +154,2 % | −735,2 % | +92,7 % | −428,2 % |
| Dividende je Aktie | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
Analysten
Einstufungen
Gerade nicht verfügbar.
Kursziel
Gerade nicht verfügbar.
Schätzungen
| FY 2026 | FY 2027 | |
|---|---|---|
| Umsatz (Ø) | 18,03 Mrd. | 20,7 Mrd. |
| Umsatz (Tief – Hoch) | 18,03 Mrd. – 18,03 Mrd. | 20,7 Mrd. – 20,7 Mrd. |
| Gewinn je Aktie (Ø) | 0,00 | 0,00 |
| Gewinn je Aktie (Tief – Hoch) | 0,00 – 0,00 | 0,00 – 0,00 |
| Analysten | 0 | 0 |
Quartalszahlen
Nächste Zahlen: 26. Nov. 2026| Sept. 2026 | Juni 2026 | Apr. 2026 | Dez. 2025 | Sept. 2025 | Juni 2025 | März 2025 | Nov. 2024 | |
|---|---|---|---|---|---|---|---|---|
| Gewinn je Aktie · Erwartet | – | – | – | – | – | – | – | – |
| Gewinn je Aktie · Tatsächlich | -0,60 | -0,60 | -0,26 | -0,20 | -0,31 | -0,28 | -0,04 | -0,28 |
| Abweichung | – | – | – | – | – | – | – | – |
| Umsatz · Tatsächlich | 338,53 Mio. | 342,26 Mio. | 403,17 Mio. | 421,41 Mio. | 447,36 Mio. | 486,19 Mio. | 526,99 Mio. | 512,95 Mio. |
Dividenden und Splits
Keine Dividenden gezahlt.
Aktiensplits
–
Eigentümer
Institutionen
Q2 2026 · 13F
- Anteil institutioneller Investoren
- 0,42 %
- Investoren mit 13F-Meldung
- 8
Größte Investoren
- CITADEL ADVISORS LLC0,20 %17.339
- RENAISSANCE TECHNOLOGIES LLC0,15 %12.914
- SERENUS WEALTH ADVISORS, LLC0,05 %4320
- UBS GROUP AG0,02 %1597
- SBI SECURITIES CO., LTD.0,00 %149
- MORGAN STANLEY0,00 %113
- JPMORGAN CHASE & CO0,00 %47
- RHUMBLINE ADVISERS0,00 %22
Insider-Geschäfte
- Chen Yang Luke28. Sept. 2026 · directorVerkauf38.120 Aktien · 0,18
- Chen Yang Luke23. Sept. 2026 · directorVerkauf44.000 Aktien · 0,18
- Chen Yang Luke23. Sept. 2026 · directorVerkauf44.000 Aktien · 0,18
- Chen Yang Luke15. Juni 2026 · directorVerkauf44.000 Aktien · 0,23
- Chen Yang Luke12. Juni 2026 · directorVerkauf49.920 Aktien · 0,23
- Chen Yang Luke27. Mai 2026 · directorVerkauf3400 Aktien · 0,25
- Chen Yang Luke26. Mai 2026 · directorVerkauf1440 Aktien · 0,27
- Chen Yang Luke12. Mai 2026 · directorKauf413.168 Aktien
Vergleichbare Unternehmen
Über das Unternehmen
Based in Shanghai, People's Republic of China, 111, Inc. (established in 2010 and formerly known as New Peak Group until April 2018) is a prominent entity in the Chinese healthcare sector, operating a comprehensive online-to-offline (O2O) ecosystem. Its operations are structured across both business-to-business (B2B) and business-to-consumer (B2C) channels. The company facilitates the sale of a wide array of medical and wellness products, reaching customers through its online retail channels as well as wholesale and retail pharmacy networks. This extensive product catalog encompasses prescription medications, over-the-counter drugs (both Western and traditional Chinese), dietary supplements like vitamins, optical products such as contact lenses, various medical supplies and devices (e.g., bandages, thermometers), personal care items (including skincare, birth control, and sexual wellness products), and infant care essentials. Beyond product sales, 111, Inc. provides value-added services to consumers, such as online consultation and electronic prescription fulfillment. For its business partners, the company manages an online marketplace enabling third-party vendors to directly supply pharmacies. It further supports its "1 Pharmacy" clients – comprising pharmacies and wholesalers – with online loan application services, alongside offering data and supply chain integration solutions. Its operational scope also extends to critical back-end functions, including warehousing, logistics management, procurement, research and development, consulting, as well as software development and IT support. As of December 31, 2021, its physical footprint included 14 retail pharmacies operating under the "Yi Hao Pharmacy" brand across several key regions: Guangzhou, Tianjin, Kunshan, Chongqing, and Wuhan. The company caters to a diverse clientele, encompassing individual consumers, pharmacies, pharmaceutical manufacturers and distributors, medical practitioners, and insurance providers.
Führung
- Gang YuCo-Founder & Executive Chairman
- Monica MuIR Director
- Alex LiuFinance Director
- Anfeng GuoChief Innovation Officer
- Junling LiuCo-Founder, Acting Chief Financial Officer, Chairman & Chief Executive Officer
- CEO
- Junling Liu
- Mitarbeitende
- 1.063
- Hauptsitz
- Shanghai, SH, CN
- Sektor
- Healthcare
- Branche
- Medical - Distribution
- Börsengang
- 12. Sept. 2018
- Website
- 111.com.cn
Nachrichten
- Defense World · 5. Nov., 1:29Comparing 111 (NASDAQ:YI) & BrightSpring Health Services (NASDAQ:BTSG)
- PRNewsWire · 26. Okt., 4:00111, Inc. Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee
- GuruFocus · 28. Sept., 5:00111, Inc. Announces Establishment of the Special Committee
- PRNewsWire · 28. Sept., 4:30111, Inc. Announces Establishment of the Special Committee
- PRNewsWire · 17. Sept., 4:25111 Inc. Receives Unsolicited Preliminary Non-Binding Proposal to Acquire the Company
- GuruFocus · 17. Sept., 4:00111, Inc. Announces Second Quarter 2026 Unaudited Financial Results
- PRNewsWire · 17. Sept., 3:00111, Inc. Announces Second Quarter 2026 Unaudited Financial Results
- Defense World · 16. Sept., 1:30Critical Review: 111 (NASDAQ:YI) and SBC Medical Group (NASDAQ:SBC)
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.